# Insulet Corporation (PODD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $147.48, market value $10.2 billion.

## Valuation
- **P/E (trailing): 27.6×** (5-yr avg 1103.0×, 3-yr avg 66.9×). Insulet Corporation trades at 27.6× trailing earnings, well below its own five-year average of 1103.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 19.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 7.2×**. The shares trade at 7.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 16.7×**. Enterprise value is 16.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.9%** (5-yr avg 0.6%). Free cash flow equals 2.9% of the market value, above its five-year average of 0.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.6%**. The inverse of the P/E: 3.6% of the price is earned each year.

## Profitability
- **Gross margin: 71.1%**. Insulet Corporation keeps 71.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 16.9%**. 16.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 9.1%**. 9.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 16.3%**. 16.3% on shareholders' equity is solid.
- **Return on invested capital: 26.6%**. Return on all capital, debt included, is 26.6%: comfortably above what that capital costs.
- **Return on assets: 11.8%**. Each dollar of assets produces 11.8% of profit.

## Growth
- **Revenue growth (1 yr): 30.7%** (3-yr 36.9%/yr, 5-yr 24.5%/yr). Revenue grew 30.7% over the last year, against 24.5% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -39.8%** (3-yr 267.7%/yr, 5-yr 103.4%/yr). Earnings per share fell 39.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Current ratio: 2.81** (quick 2.81). Current assets cover the next year's liabilities 2.81 times.
- **Altman Z-score: 6.13**. A Z-score of 6.13 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Insulet Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -57.4%** (YTD -48.1%, 3-mo -3.7%). The shares are down 57.4% over twelve months including dividends.
- **From 52-week high: -58.4%** (16.7% above the low). Trading 58% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 0.28** (volatility 44%). Beta of 0.28 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PODD · Page: https://foliofundamentals.com/stocks/podd

Not investment advice.